|
|||||
|
|
A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile |
|
| Authors: | Kevin W. McConeghy Melinda M. Soriano Larry H. Danziger |
| Affiliation: | 1. Providence VA Medical Center, Providence, Rhode Island;2. Brown University School of Public Health, Providence, Rhode Island;3. Global Center for Scientific Affairs, Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey;4. Colleges of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, Illinois |
| Abstract: | |
| Keywords: | Clostridium difficile alendronate risedronate bisphosphonate colitis |